Osman Moneer

Stanford University — United States

Economics, Econometrics and Finance · Social Sciences

7h-index144citations18works0.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Health Systems, Economic Evaluations, Quality of Life(9), Pharmaceutical Economics and Policy(6), Healthcare Policy and Management(4), Meta-analysis and systematic reviews(3), Biomedical Ethics and Regulation(3)

Publications18 total

Therapeutic Benefit Ratings for FDA Breakthrough-Designated Devices
JAMA Surgery·2026Open Access
Hospital Acquisition Costs for Breakthrough-Designated Devices Awarded Supplemental Medicare Reimbursement
JAMA Health Forum·2025Open Access
Research Derived From Medicare’s Coverage With Evidence Development Program
JAMA Network Open·2025Open Access
Characterization of studies considered and required under Medicare’s coverage with evidence development program
Clinical Trials·2025
Voting Trends Among Otolaryngology–Head and Neck Surgery Trainees
Laryngoscope Investigative Otolaryngology·2025Open Access
Assessing Medicare’s Coverage With Evidence Development Program
Health Affairs·2025· 1 cited
Medicare Local Coverage Determinations: Evidence Quality Is Stronger For Covered Indications
Health Affairs·2024· 2 cited
Medical Devices Applying for Outpatient Medicare Supplemental Payments
JAMA Health Forum·2024· 1 citedOpen Access
HPR109 Evaluation of Evidence Informing Medicare’s Coverage With Evidence Development Decision Updates
Value in Health·2024
Aligning US Agency Policies for Cardiovascular Devices Through the Breakthrough Devices Program
JAMA Cardiology·2023· 15 cited
Fulfillment of Postmarket Commitments and Requirements for New Drugs Approved by the FDA, 2013-2016
JAMA Internal Medicine·2022· 10 citedOpen Access
Generating evidence during a pandemic: what’s reliable?
BMJ·2022Open Access
Agreement of treatment effects from observational studies and randomized controlled trials evaluating hydroxychloroquine, lopinavir-ritonavir, or dexamethasone for covid-19: meta-epidemiological study
BMJ·2022· 21 citedOpen Access
New Drug Postmarketing Requirements and Commitments in the US: A Systematic Review of the Evidence
Drug Safety·2022· 17 cited
Direct-to-consumer personal genomic tests need better regulation
Nature Medicine·2021· 13 cited
Characteristics of Postmarketing Studies for Vaccines Approved by the US Food and Drug Administration, 2006-2020
JAMA Network Open·2021· 2 citedOpen Access
An Overview Of Vaccine Development, Approval, And Regulation, With Implications For COVID-19
Health Affairs·2020· 55 cited
Covid-19, single-sourced diagnostic tests, and innovation policy
Journal of Law and the Biosciences·2020· 7 citedOpen Access

Frequent Co-authors

Joseph S. Ross(10), Sanket S. Dhruva(8), Maryam Mooghali(5), Reshma Ramachandran(5), Aaron S. Kesselheim(4), Jerry Avorn(4), Guneet Janda(4), Jonathan J. Darrow(3), Beatrice L. Brown(3), Mayookha Mitra-Majumdar(3), Vinay K. Rathi(3), ChangWon C. Lee(2), Joshua D. Wallach(2), Catherine Pham(2), James L. Johnston(2), Kushal T. Kadakia(2), James Burke(2), Martin Kulldorff(1), Garrison Daly(1), Joshua J. Skydel(1)